StockNews.AI
ORN
StockNews.AI
109 days

301,521 Orion Corporation A shares converted into B shares

1. 301,521 A shares converted into B shares as of May 2, 2025. 2. Total shares now number 141,134,278 with voting rights updated. 3. Orion's 2024 net sales were EUR 1,542 million. 4. Company focuses on oncology and pain management pharmaceuticals. 5. Orion employs about 3,700 professionals globally.

3m saved
Insight
Article

FAQ

Why Neutral?

The share conversion itself does not directly impact the company's value but could affect voting power and liquidity. Historical examples show such conversions typically do not result in immediate price changes.

How important is it?

The conversion indicates corporate governance activity rather than financial performance. Investors may still monitor the company's pipeline and sales for genuine value changes.

Why No Impact?

The conversion is an administrative action rather than a fundamental change. Similar past actions by companies have had minimal short- or long-term market effects.

Related Companies

ORNBHPHMSNY
May 02, 2025 02:00 ET  | Source: Orion Oyj ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE2 MAY 2025 at 9.00 EEST                  301,521 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 301,521 A shares have been converted into 301,521 B shares. The conversion has been entered into the Trade Register on 2 May 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 32,450,742 A shares and 108,683,536 B shares. The number of votes of the company's shares is after the conversion 757,698,376. Orion Corporation René LindellCFO     Olli HuotariEVP, Corporate Functions                                                     Contact person:Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721  Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandwww.orionpharma.com Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.

Related News